A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
NCT ID: NCT07105059
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
18 participants
INTERVENTIONAL
2025-08-08
2028-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488
Marizomib Central Nervous System (CNS)
NCT05050305
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NCT06050512
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Teclistamab and Mezigdomide
The trial treatment will start with 14 days of mezigdomide priming to sensitize the myeloma cells to the bispecific antibody treatment and to stimulate and activate T-cells. After mezigdomide priming, patients will go through the step-up dosing with teclistamab- followed by combination treatment with both drugs.
Teclistamab
After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
Mezigdomide
Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Teclistamab
After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
Mezigdomide
Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients need to have measurable disease defined by one or more of the following:
1. Serum myeloma (M)-protein greater than or equal to 0.5 g/dL (5 g/L).
2. Urine M-protein greater or equal to 200 mg/24 h.
3. Involved light chain (either kappa or lambda) \>10 mg/dL with an abnormal kappa: lambda ratio
4. Plasmacytoma(s) that is new or definitely increased verified by imaging or biopsy.
Increase is defined as a 50% and at least 1 cm increase as measured serially by the sum of the products of the cross-diameters of the measurable lesion.
5. A bone marrow biopsy demonstrating \>30% infiltration of clonal plasma cells.
3. Patients who have received prior BCMA-directed therapy \> 90 days prior including antibody drug conjugates or chimeric antigen receptor T-cell \[CAR T\] are eligible. BCMA presence on the cell surface should be confirmed in patients who have been treated with prior BCMA targeted therapies. Prior treatment with BCMA targeted bispecific antibodies is not allowed.
4. Patients who have received bispecific antibodies \>60 days prior with targets other than BCMA are eligible.
5. Patients who have received allogeneic stem cell transplantation \>6 months prior are eligible.
6. Age ≥18 years.
7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1. PS-2 is permitted if PS is due solely to bone pain.
8. Fulfil the criteria for Adequate Organ System Function Based on Safety Assessments:
Hematologic:
* Hemoglobin ≥8 g/dL (without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted)
* Absolute neutrophil count (ANC) ≥1.0 × 109/L (prior growth factor support is permitted but must be without support for 7 days for G-CSF or GM-CSF and for 14 days for pegylated-G-CSF) before the screening and laboratory test
* Platelets ≥75 × 10\^9/L in participants in whom \<50% of bone marrow nucleated cells are plasma cells and ≥50×109 /L in participants in whom ≥50% of bone marrow nucleated cells are plasma cells (without transfusion support or thrombopoietin receptor agonist within 7 days before the screening laboratory test)
Chemistry:
* Total bilirubin ≤2 × ULN; except in subjects with congenital bilirubinemia, such as Gilbert syndrome (in which case if total bilirubin is \>2×ULN, then direct bilirubin ≤1.5×ULN is required)
* AST and ALT ≤2.5 × ULN
* eGFR ≥30 mL/min Calculated by CKD-EPI formula adjusted for body surface area (BSA): (mL/min/1.73 m2) x BSA/1.73)
* Serum calcium corrected for albumin ≤14 mg/dL (≤3.5 mmol/L) or free ionized calcium ≤6. mg/dL (≤1.6 mmol/L)
9. Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤ 1, with the exception of peripheral neuropathy attributable to bortezomib.
10. Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
° Is not a woman of childbearing potential (WOCBP)
Nonchildbearing potential is defined as follows (by other than medical reasons):
* ≥45 years of age and has not had menses for \>1 year
* Patients who have been amenorrhoeic for \<2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation
* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure OR
* Is a WOCBP and agrees to use two different contraceptive methods that are highly effective (with a failure rate of \<1% per year), preferably with low user dependency , during the intervention period and for at least 6 months after the last dose of study intervention.
* WOCBP must have two negative serum or urine pregnancy tests with 10-14 days in between prior to treatment with mezigdomide. The latter must be within 15 days of starting mezigdomide. WOCBP must agree to use two highly effective methods of contraception (i.e. copper-containing intrauterine device, established use of oral, inserted, injected or implanted hormonal method of contraception, or male/female sterilization, etc.
* WOCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy. Pregnancy prevention while on mezigdomide treatment is All WOCBP must agree and adhere to all testing and contraception requirements in the mezigdomide Global Pregnancy Prevention Plan (PPP). Duration of contraception for WOCBP must be in accordance with the mezigdomide Global PPP
11. Male participants: Male participants are eligible to participate if they agree to the following: male participants must agree to practice complete abstinence or agree to use a condom during sexual contact with a pregnant partner or an WOCBP while taking mezigdomide, during dose interruptions, and for 28 days after the last dose of mezigdomide, even if they have undergone a successful vasectomy (ie, with documented azoospermia 90 days after the procedure). See mezigdomide Global PPP, Appendix 3. Male participants must agree not to donate sperm for the purpose of reproduction during this period.
12. Signed and dated Informed Consent by study participant.
13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures.
Exclusion Criteria
2. Prior treatment with mezigdomide
3. Systemic anti-myeloma therapy (including systemic steroids) within ≤14 days, or plasmapheresis within 7 days prior to the first dose of study drug.
4. Use of an investigational drug within 21 days or five half-lives (whichever is longer) preceding the first dose of study drug.
5. Radiation therapy within ≤14 days prior to study entry (bone lesions requiring radiation may be treated with limited \[i.e., ≤ 25% of bone marrow in field\] radiation therapy during this period).
6. Live, attenuated vaccine or investigational vaccine within 4 weeks before the first dose of study drug. Non-live or non-replicating vaccines authorized for emergency use (eg, COVID-19) by local health authorities are allowed
7. Patients with a history of autologous stem cell transplant within 60 days or allogeneic stem cell transplant within 6 months prior to study enrollment.
8. Patients who received CAR T therapy within 90 days prior to study enrollment
9. Patients with primary AL amyloidosis will be excluded.
10. Participant must not have had major surgery ≤4 weeks prior to initiating study treatment.
11. Evidence of active internal bleeding.
12. Presence of active renal condition. Participants with isolated proteinuria resulting from multiple myeloma are eligible, provided they fulfill criteria given
13. Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease per investigator's assessment).
14. Subject has active or prior history of malignancy, other than multiple myeloma, unless the subject has been free of the disease or medically stable for ≥ 2 years. The only allowed exceptions are the below listed malignancies treated within the last 24 months and that are considered cured:
* Non-muscle invasive bladder cancer
* Non-melanoma skin cancers treated with curative therapy or localized melanoma treated with curative surgical resection alone
* Carcinoma in situ of the cervix
* Carcinoma in situ of the breast
* Localized prostate cancer (M0, N0) with a Gleason Score ≤7a, treated locally only (RP/RT/focal treatment) The participant must not be receiving active therapy, other than hormonal therapy for this disease. Presence of low risk prostate cancer per NCCN on active surveillance is permitted.
15. Evidence of cardiovascular risk including any of the following:
* Evidence of current clinically significant untreated arrhythmias, including clinically significant ECG abnormalities including 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block.
* History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening
* Stroke, transient ischemic attack, or seizure within 6 months prior to randomization
* Class III or IV heart failure as defined by the New York Heart Association functional classification system.
16. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to teclistamab or mezigdomide, or any of the components of the study treatment.
17. Pregnant or lactating individual.
18. Active infection requiring treatment.
19. Participant has known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:
1. Established antiretroviral therapy (ART) for at least 6 months and HIV viral load \<400 copies/mL, and
2. CD4+ T-cell (CD4+) counts ≥350 cells/μL, and
3. No history of acquired immunodeficiency s-defining opportunistic infections or other acquired immune deficiency syndrome (AIDS)-defining conditions within the last 12 months and
4. Not receiving highly active anti-retroviral therapy, and
5. Not receiving antiretroviral therapy that may interfere with study treatment
20. Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb at Screening or within 3 months prior to first dose of study treatment). Note: Participants with positive Hepatitis B antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis B DNA test is obtained.
21. Active Hepatitis C infection as measured by positive hepatitis C virus (HCV)-RNA testing. Subjects with a history of HCV antibody positivity must undergo HCV RNA testing. The result needs to be negative for trial eligibility.
22. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.
23. Administration of strong CYP3A modulators or proton-pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) within 2 weeks of starting study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Johnson & Johnson
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malin Hultcrantz, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Ross Firestone, MD, PhD, MS
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Malin Hultcrantz, MD, PhD
Role: primary
Malin Hultzcrantz, MD, PhD
Role: primary
Malin Hultcrantz, MD, PhD
Role: primary
Malin Hultcrantz, MD, PhD
Role: primary
Malin Hultcrantz, MD, PhD
Role: primary
Malin Hultcrantz, MD, PhD
Role: primary
Malin Hultcrantz, MD, PhD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-393
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.